First, we established sensitivity to lapatinib treatment of ErbB2-positive lung and breast cancer cell lines, identified an array of putative acquired resistance mutations and demonstrated that mutations of ErbB2-T798 lead to resistance that can be overcome by the irreversible ErbB2 inhibitor, PD168393. Here, ERBB2 is linked to breast cancer.